CuNA: Cumulant-based Network Analysis of genotype-phenotype associations in Parkinson's Disease

Aritra Bose^{1,†}, Daniel E. Platt^{1,†}, Niina Haiminen¹, and Laxmi Parida^{1,*}

¹Computational Genomics, IBM T.J Watson Research Center, Yorktown Heights, NY 10598 [†]Equal contribution

^{*}Corresponding author: parida@us.ibm.com

Abstract

Parkinson's Disease (PD) is a progressive neurodegenerative movement disorder characterized by loss of striatal dopaminergic neurons. Progression of PD is usually captured by a host of clinical features represented in different rating scales. PD diagnosis is associated with a broad spectrum of non-motor symptoms such as depression, sleep disorder as well as motor symptoms such as movement impairment, etc. The variability within the clinical phenotype of PD makes detection of the genes associated with early onset PD a difficult task. To address this issue, we developed CuNA, a cumulant-based network analysis algorithm that creates a network from higher-order relationships between eQTLs and phenotypes as captured by cumulants. We also designed a multi-omics simulator, CuNAsim to test CuNA's qualitative accuracy. CuNA accurately detects communities of clinical phenotypes and finds genes associated with them. When applied on PD data, we find previously unreported genes INPP5J, SAMD1 and OR4K13 associated with symptoms of PD affecting the kidney, muscles and olfaction. CuNA provides a framework to integrate and analyze RNA-seq, genotype and clinical phenotype data from complex diseases for more targeted diagnostic and therapeutic solutions in personalized medicine. CuNA and CuNAsim binaries are available upon request.

1 Introduction

1

A primary goal in complex disease genetics is to understand how genes influence the symptoms, that is, the mapping from genotype to phenotype. The knowledge about etiology and pathogenesis of a disease provides a basis for targeted treatment and prevention. Casecontrol genome wide association studies (GWAS) and whole-exome sequencing (WES) are useful methods to understand the rare causative mutations that underlie complex diseases with small effects from common variants [1]. Quantitative Trait Loci (eQTL) studies bridge these methods by enabling investigation of the effect of the genotypes or risk loci on gene expression levels and how, in turn, they affect phenotypes [2]. expression eQTL analysis is used to determine hotspots, construct causal networks, discover stratification in clinical phenotypes and select genes for clinical trials [3]. The application of these methods have revealed a significant number of risk loci [4–6] in complex diseases.

Parkinson's Disease (PD) is such a complex neurological disorder affecting approximately 13 1.2% of the world's septuagenarian population. PD has a rapid progression characterized by 14 motor symptoms due to loss of dopaminergic neurons in the substantia nigra and presence of 15 Lewy bodies [7], bradykinesia, rigidity and tremor [8]. PD progresses from early symptoms 16 such as mild non-motor manifestations to significant degenerative effects on mobility and 17 muscle control [9] in advanced stages. The progression of symptoms of PD is tracked by 18 rating scales which asses different stages of the disease. The most widely accepted rating 19 scale is the Hoehn and Yahr (HY) scale [10], while another comprehensive assessment scale 20 is the Unified Parkinson's Disease Rating Scale sponsored by the Movement Disorder Society 21 (MDS-UPDRS) [11]. Recently, over 41 genetic susceptibility loci have been associated with 22 late-onset PD in the largest GWAS meta-analysis up to date [12]. Few genes have been found 23 to be causal among these risk loci, but for majority of loci, it is not yet known which genes 24 are linked with PD risk. Moreover, despite concerted efforts in understanding the genomic 25 processes underlying the progression of the disease, the clinical heterogeneity of PD makes it 26 elusive. There is a complex interaction between motor and non-motor symptoms, with both 27 impacting key issues such as sleep, constipation, depression and muscle movement [13, 14]. 28 It has also been hypothesized that PD actually comprises two subtypes, brain-first or body-29 first [15]. Due to this heterogeneity in clinical features and their trajectories, it is important 30 to understand the biological processes underlying these groups of features and symptoms. 31

To this end, we developed CuNA, namely, Cumulant-based Network Analysis. CuNA finds higher order genotype-phenotype interactions by integrating genes implicated in the disease as obtained from GWAS or eQTL studies and the associated phenotypes or clinical features.

Hence, we find groups of features from the similar subsets of subjects using logical relation-35 ships among features called "redescription" clusters and subsequent cumulant computations. 36 CuNA performs community detection on the network constructed from the significant higher-37 order interactions between clinical features and genes related to the disease. To show that 38 CuNA accurately captures the interaction between the biomarkers and phenotypes, we de-39 signed CuNAsim, a simulator for gene expression, genotypes and phenotypes. CuNAsim is a 40 multi-omics simulator which simulates genomics and transcriptomics data accounting for en-41 dophenotypes. It also captures eQTLs and relationships between omics data with an array of 42 clinical phenotypes. Although in framework it is similar to a prior multi-omics simulator [16], 43 CuNAsim provides simulation scenarios with relative correlation of each phenotype with a 44 user defined set of biomarkers (genes and genotypes). 45

To disentangle the effects of heterogeneity of PD, we applied CuNA to the collection of 46 data from the Parkinson's Progression Markers Initiative (PPMI) study (https://www.ppmi-47 info.org). We found several novel genes associated with a collection of PD phenotypes. Al-48 though previous work has demonstrated success in predicting PD status from gene expression 49 data (e.g. [17]), associations of genes with the phenotypic measurements underlying PD di-50 agnosis have not been reported before at this level of granularity. CuNA enables us to find 51 such interactions which are often not captured by traditional GWAS, highlighting the clinical 52 heterogeneity of the disease. Although, we apply CuNA to understand the biological under-53 pinnings of motor and non-motor symptoms of PD, the method can be applied to a host of 54 complex diseases which are captured by an array of clinical features, symptoms, environmen-55 tal and behavioral effects such as Alzheimer's Disease, Coronary Artery Disease ad metabolic 56 syndrome, Cancer and other neurological disorders. CuNA finds biomarkers associated with 57 these clinical and non-genetic features paving the path for future biomarker discovery and 58 therapeutics for complex diseases. 59

- $_{60}$ 2 Methods
- $_{61}$ 2.1 CuNAsim

62 CuNAsim is a multi-omics simulator integrating phenotypes, genotypes, and gene expres-63 sion levels. To handle the integration of different omics data we started with a multivariate 64 distribution

$$f(x)d^{d}x = \sqrt{\frac{\det(A)}{(2\pi)^{d}}} \exp\left(-\frac{1}{2}(x-\mu)^{T}A(x-\mu)\right)d^{d}x$$
(1)



Figure 1: Overview of the study design with CuNA playing a central role. Inputs are colored in orange and output in blue.

Components of x were identified as phenotypic (binary, which may include environmental 65 conditions as well), SNP (pairs of binary alleles, one for each of the chromosome pairs), or 66 gene expression (floating). Covariances A^{-1} were specified in terms of $A = \sigma \operatorname{cor}(x, x^T) \sigma$ where 67 the σ is a diagonal matrix with values representing the spread of the variates, and $cor(x, x^T)$ 68 is specified to yield correlations among phenotypes, alleles between each pair of chromosomes 69 representing Hardy-Weinberg disequilibrium, and among gene expression levels reflecting co-70 regulation among pathways. Correlations between phenotypes, SNPs and expression levels 71 reflect interactions including allele impacts on expression levels, relationships between SNPs, 72 expression levels, and disease/phenotype processes, driven by biological pathways. Offsets μ 73 set quantities such as MAF, case/control proportions, and expression level centers. Binary 74 values were mapped from $I(x_i \ge 0)$. The fraction of cases are $E(I(x_i \ge 0))$. Genotypes were 75 mapped from $I(x_I \ge 0) + I(x_{i+1} \ge 0)$. MAF is then $E(I(x_i \ge 0))$. ORs may be derived 76 from the joint probabilities $E(I(x_i \ge 0 \land x_j \ge 0))$ for SNP values x_i . Expression levels were 77 mapped to $\exp(x_i)$. 78

We simulated three different simulation scenarios for 1,000 samples and 11 features (3 phenotypes, 3 SNPs and 5 genes with varying expression levels). Although CuNAsim can generate high dimensional data we restricted our toy simulation to demonstrate the accuracy of CuNA in picking out the genotype-phenotype interactions with the highest Pearson correlation

coefficient (r^2) and to demonstrate its robustness in presence of false positives and correcting 83 for spurious associations. To achieve this objective we designed three scenarios with varying 84 correlations. In the first scenario, we designed an extreme case where only a few features among 85 the genes, SNPs and phenotypes were highly correlated with each other (inset in Figure 2). 86 In the second case, we took an average case where many of the features were moderately 87 correlated with each other (Supplementary Figure 5). For the third case we performed a 88 sanity check with completely uncorrelated features, therefore, the resulting correlation matrix 89 being equal to an identity matrix. 90

91

2.2 Parkinson's Disease Data

92 RNA-seq expression data

We compiled RNA-seq gene expression data from the PPMI phase 2 release containing 4,649 93 blood-based samples across five visits and 34,386 genes with Transcripts per million (TPM) 94 values. PPMI annotates samples with labels reflecting whether they are from de novo PD 95 subjects (subjects diagnosed with PD for two years or less and are not taking PD medications; 96 annotated as PD) and from control subjects without PD who are 30 years or older and do not 97 have a blood relative with PD diagnosis (annotated as HC). We used PD (n=293) and HC 98 (n=163) samples only from the baseline visit for our analyses as the number of overlapping 99 samples with genotype and gene expression data for other visits were low. 100

101 Genotype data

The genotype data released in Phase 1 of PPMI contained 960 individuals and approximately 44 million high quality Single Nucleotide Polymorphisms (SNPs) that passed GATK VQSR quality control. We further filtered SNPs with missing genotyping rate > 0.02 for SNPs and individuals, respectively and Minor Allele Frequency (MAF) > 0.05, Hardy-Weinberg equilibrium > 1e - 6 and removed individuals with heterozygosity rates with more than three standard deviations from the mean resulting in 5.6 million SNPs. We only selected PD and HC samples having baseline gene expression data, 456 individuals.

109 **2.3** CuNA

CuNA integrates the phenotypes related to PD (or any disease) along with the genetic variants or genes as features, and computes higher-order associations between these features to find subsets of features influencing groups of individuals with similar underlying biological

113	pathways. An outline of the algorithm is given in Algorithm 1. CuNA computes cumulants
114	and construct networks with only statistically significant connections between any two pair of
115	features i and $j.$ It computes $N_{i,j}$ as a tuple of number of cumulant groups containing both i
116	and j denoted as $n_{i,j}$, number of cumulant groups containing only i: $n_{i,*}$, number of cumulant
117	groups containing only $j: n_{*,j}$ and number of cumulant groups without either of i or j . This
118	allows us to compute a Fisher's exact test and obtain significance parameters for each pair \boldsymbol{i}
119	and \boldsymbol{j} and whether the edge between them in a network would be at random. We form the
	network with pairs of features which has a $p < 0.05$ in the Fisher's exact test.

Algorithm 1 CuNA: Cumulant-based Network Analysis

Input: Set of k features $\mathbf{Y} = y_1, y_2, \dots, y_k$ containing candidate genes and phenotypes of PD. **Output:** Communities, $\mathbf{M} = m_1, m_2, \dots, m_p$ of interactions between the genes and phenotypes.

- 1: Compute G's (Equation 3) to identify higher-order interactions between \mathbf{Y} .
- 2: Perform permutation tests and obtain \mathbf{F} , statistically significant subsets of features.
- 3: Construct network and detect communities: $\mathbf{M} = \text{NetCoDe}(\mathbf{F})$
- 4: Annotate M to discover biological pathways underlying candidate genes and phenotypes.

Algorithm 2 NetCoDe: Network formation and community detection

Input: $\mathbf{F} = f_1, f_2, \dots, f_l$ where f_i is a group of k features denoted by $f_i = f_{i_1}, f_{i_2}, \dots, f_{i_k}$. **Output:** Communities, $\mathbf{M} = m_1, m_2, \dots, m_p$ of interactions between the genes and phenotypes.

- 1: **FOR** all *l* groups of features:
- 2: **FOR** all (i, j) pair of $\binom{k}{2}$ features:
- 3: Compute $N_{i,j} = n_{i,j}, n_{*,j}, n_{i,*}, n_{*,*}$
- 4: Obtain p-value $p_{i,j}$ Fisher's exact test on $N_{i,j}$
- 5: **IF** $p_{i,j} < 0.05$
- 6: $\mathbf{E} \cup e_{i,j}$
- 7: $\mathbf{V} \cup v_i, v_j$
- 8: **END IF**
- 9: END FOR
- 10: END FOR
- 11: Build a network, $\mathbf{G} = (\mathbf{V}, \mathbf{E})$ where vertices (\mathbf{V}) are features f_i and f_j and the edge (\mathbf{E}) between them have weights $c_{i,j}$.
- 12: Perform community detection using Girvan-Newman method [18] and obtain M communities.

121 2.4 Study design

¹²² CuNA is a framework to study the genetic factors influencing the clinical features of a complex

disease, in this case, PD with its motor and non-motor symptoms. As a first step, we take

- the genotype data as well as the RNA-seq gene expression data as input and compute eQTLs.
- ¹²⁵ We extract significant *cis-eGenes* (above a predefined statistical significance threshold) and
- include them as features with the phenotypic measurements related to PD. Thereafter, we ap-

¹²⁰

ply CuNA (Cumulant-based Network Analysis) as a meta-analysis method on these candidate
genes and phenotypic features in order to draw higher-order associations between them. We
construct a network as part of CuNA and perform community detection on the network to
obtain communities or clusters of interacting features (genes and phenotypes). Further gene
ontology analysis is performed on these interacting genes to obtain the biological pathways
highlighted for similar symptoms or features in PD. The outline of our approach is detailed
in Figure 1.

134 Computing eQTLs

We used Matrix eQTL [19] for fast eQTL analysis on 34,386 genes and 5.6 million SNPs across 135 456 individuals. For all of our eQTL analysis we used p-value threshold of 1×10^{-7} and FDR 136 < 0.05 and a distance of 1×10^6 base pairs in which the gene-SNP pair would be considered 137 local and tagged as *cis*-eQTL (Supplementary Figure 1). Matrix eQTL tests for association 138 between each SNP and transcript by modeling the effect of genotype as either additive linear 139 or categorical. We computed the top 20 Principal Components (PCs) of the genotype data 140 using TeraPCA [20] and included them along with age and gender information as covariates 141 to correct for latent population structure (Supplementary Figure 2). 142

¹⁴³ Supervised classification

We used machine learning approaches from Python's scikit-learn 0.23.2 package to classify HC 144 from PD on 456 individuals (293 PD and 163 HC), with 25% of the data used for validation. We 145 applied the Synthetic Minority Oversampling Technique (SMOTE) [21] to balance the PD and 146 HC classes as we have more cases than controls. We used a host of classifiers such as Random 147 Forest, Linear Regression, Ridge Regression, Support Vector Machine (SVM) with linear 148 and Radial Basis Function (RBF) kernels, etc. on the training data set and performed five-149 fold cross validation (CV) for finding optimal hyper-parameters. We performed permutation 150 tests using scikit-learn's model selection for classification to obtain statistical significance (p-151 value) of the performance of the chosen classifier using CV. Once these subsets of features 152 are identified, we obtain statistical significance of each such group by permutation tests and 153 from the significant subsets of features (p < 1e - 6, FDR < 0.05 and |Z| > 3), we construct a 154 network. 155

CuNA builds the networks between the features and the edge weights between any two feature representing the number of times these features have grouped together in all the subsets of features in the cumulant computation. The interaction network thus can be very

dense with a total of $\binom{k}{2}$ edges with k features. We thus allow only a small percentage of 159 edges until we have observed all k features due to ease of visualization and analysis. On this 160 network, we perform community detection using the algorithm described in Algorithm 2 and 161 analyze each such community drawing latent interactions between genes and the symptoms 162 or clinical features of the disease. 163

 $\mathbf{2.5}$ 164

Cumulants

We seek to identify distinct groups of individuals whose pattern memberships may give hints 165 to underlying pathways involved with disease processes. Relationships between the roles of 166 these features defining the patterns are revealed in how multiple patterns capture the same 167 groups of subjects, called redescriptions (Details in Appendix A). Since most of the progression 168 markers collected in the PPMI are strongly correlated, and we need to factor out those strong 169 lower-order correlations from higher order associations marking distinct groups of individuals 170 differentiating disease processes as their Parkinson's advances. 171

One approach towards such a factorization is suggested through a convergence of a number 172 of fields of study. Correlation expansions emerge naturally in quantum field theory, expressed 173 as a series of Feynman diagrams. These factored moments, essentially higher-dimensional 174 cumulants, may be factored to represent a set of "one-particle-irreducible" (1PI) diagrams [22]. 175 Such emerge naturally in statistics of large deviations through Cramér's theorem [23], which 176 also connects to the notion of "effective actions" from quantum field theory. Their generating 177 functions satisfy useful set partition relationships, and have been a part of traditional statistics 178 for some time [24]. 179



This factorization is represented by a moment generating function

$$\mathbb{E}\left[\exp\left(\sum_{j}F_{j}J_{j}\right)\right] = A + \sum_{l}J_{l}G_{l} + \frac{1}{2!}\sum_{ll'}J_{l}J_{l'}G_{ll'} + \frac{1}{3!}\sum_{ll'l''}J_{l}J_{l'}J_{l''}G_{ll'l''} + \frac{1}{4!}\sum_{ll'l'''l'''}J_{l}J_{l'}J_{l''}J_{l'''}G_{ll'l''l'''} + \cdots \right]$$

$$= \exp\left(\sum_{l}J_{l}K_{l} + \frac{1}{2!}\sum_{ll'}J_{l}J_{l'}K_{ll'} + \frac{1}{3!}\sum_{ll'l'''}J_{l}J_{l'}J_{l''}K_{ll'l''} + \frac{1}{4!}\sum_{ll'l''''}J_{l}J_{l''}J_{l'''}K_{ll'l'''} + \frac{1}{4!}\sum_{ll'l'''''}J_{l}J_{l''}J_{l'''}K_{ll'l'''} + \cdots\right)$$

$$(2)$$

where the F_j are features indexed by j (defined in Algorithm 1), the G's represent moments, 181 A is a constant offset (unity in this case) defined by J = 0, and the K's represent higher order 182 cumulants, e.g. $G_{ij} = E(x_i x_j)$ and $G_{ij\kappa} = E(x_i x_j x_{\kappa}^2)$, and the K_{ij} and $K_{ij\kappa}$ would be the 183

corresponding cummulants. These may be extracted in terms of the power series to yield

We apply this factorization to patterns, and test significance constructing null hypotheses and variances by shuffling phenotypes.

187 **2.6** Redescription clusters

184

203

Subjects $s \in S$ are described by a list of features $f_i(s)$ indexed by feature labels $i \in \mathcal{F}$. Each feature has an alphabet \mathcal{A}_i so that $f_i(s) \in \mathcal{A}_i$ which is often binary, but could be defined on the reals. Examples of binary features in \mathcal{F} are diagnoses (Dx) such as PD or other motor and non-motor, symptoms, blood pressure, etc. which would have a continuum alphabet $(\mathcal{A}_{bmi} = \mathbb{R})$.

For a given $a_i \in \mathcal{A}_i$, the set of subjects that have that value is $f_i^{-1}(a_i) \subseteq \mathcal{S}$. So the list of subjects with PD can be written $f_{PD}^{-1}(1)$. In the case of continuous variables, the selection of sets is according to a threshold, such as the mean $m(f_i(S))$, mapped to 1 if $f_i(s) \ge m(f_i(S))$.

Patterns may be described in terms of conjunctions $i \wedge j$ for $i, j \in \mathcal{F}$ such that $f_{i \wedge j}^{-1}(a_i, a_j) = f_i^{-1}(a_i) \cap f_j^{-1}(a_j)$ for binary a_i, a_j . This definition is extended to include either atomic i, j, such as PD or T2D, or to any combinations of conjunctions subject to the logical algebra of \wedge (e.g. $(i \wedge j) \wedge (i \wedge k) = i \wedge j \wedge k$ for $i, j, k \in \mathcal{F}$ subject to values a_i, a_j, a_k . So we can specify the PD subjects with a motor or non-motor symptom such as walking or handwriting as $f_{Walk \wedge PD}^{-1}(Walk = 1, PD = 1)$. Such combinations of conjunctions i that have more or less members $f_i^{-1}(a)$ than expected by chance are called patterns.

Binomial and other tests of the significance of patterns can be dominated by lower-order

correlations among the variables in a pattern. Two distinct patterns that yield the same subsets of subjects, e.g. $f_i^{-1}(a) = f_j^{-1}(a)$, are called "redescriptions." If conjunctions yield a form such as $A \cap B = B$, then it may be deduced that $B \subset A$, and the conditions yielding A and B satisfy $b \Rightarrow a$. In other words, redescriptions can reveal logical relationships among features. Such relationships may reflect underlying biological pathways reflected in these connected phenotype patterns. Therefore, each of these patterns *i* specify a phenotype, which may be associated with genotypes or other -omic data using standard methods.

Given the presence of misclassifications, differential evolution of disease stages, simple transcription mistakes, etc, result in errors in estimates of $f_i^{-1}(a)$ must be accounted for in estimating equivalence. We can use Jaccard distances $d = 1 - \frac{|A \cap B|}{|A \cup B|}$ measures deviations. So $d(A \cup B, B) = 1 - \frac{|A \cup |}{|B|}$ is 0 if $B \subseteq A$, some non-zero value with any $B \nsubseteq A$. This distance measures the probability that samples drawn from A and B are not shared, which gives an index for the possible to distinguish disruption due to errors, or whether it would be possible to distinguish non biological pathways vs. biological pathways with error.

218

2.7 Pathway Analysis

We performed gene ontology by doing pathway enrichment analysis of the 24 cis-genes using the package clusterProfiler 3.8 [25] in Rwith the KEGG database [26], with p < 0.05 and Benjamini-Hochberg false discovery rate adjustment.

3 Results

3.1 Simulation study

We applied CuNA on the data simulated by the multi-omics simulator CuNAsim which was 224 developed particularly for integrating genomics, transcriptomics and phenotypes. In the first 225 scenario we allowed only a few highly correlated interactions between the features such as 226 $(Gene \theta - SNP \theta)$ with $r^2 = 0.9$, $(Gene \theta - SNP 2)$ with $r^2 = 0.8$, $(Pheno \theta - Pheno 1)$ 227 with $r^2 = 0.6$, etc. Using the simulated data from the first scenario as an input to the CuNA 228 pipeline, we found the resulting embedded network from higher order interactions captures all 229 the aforementioned interactions (Figure 2). Running the community detection algorithm on 230 the network (Figure 2) we found the following communities: 231

232 – Gene0, SNP2, Pheno2

233 – *SNP0*



Figure 2: Network of the simulated variables from the first scenario with highly correlated features. The nodes are colored by degrees (darker colors have higher degree). The correlation matrix of the variables is shown in the inset with the color gradient.

234 – Pheno0, Pheno1

Thus, CuNA captures the communites accurately as reflected in the network (Figure 2) as well as the original correlations which was the input to Algorithm 1.

For the average case with moderately correlated interactions between features as shown in Supplementary Figure 5, we see a similar behavior when we applied CuNA. It captures the highly correlated interactions such as (Gene0 - SNP1), (Gene0 - Gene1), (Gene2 - Pheno1), etc. The communities also reflected clusters of biomarkers and phenotypes which followed the input correlation matrix as shown in the inset of Supplementary Figure 5. They were:

- 243 Gene0, Gene1, Gene2, SNP1, Pheno2
- 244 SNP0, Pheno0
- 245 Pheno1

For another extreme case of no correlation between the features we found none of the interactions crossed our user defined threshold of p < 1e - 6, |Z| > 3 and FDR< 0.05. As expected, CuNA failed to observe anything significant from uncorrelated features even when we increased the parameters for checking false positive associations. The parameters for generating the simulated correlations with mean μ and standard deviation σ for each feature is

detailed in Supplementary Tables B-D for the first simulation scenario and in Supplementary
 Tables E-G for the second scenario.

3.2 Selecting predictive *cis-eGenes*

We computed eQTLs on the 456 PD and HC individuals having genotype and gene expression 254 data from the baseline visit. We obtained 24 *cis* and 53,550 *trans* significant SNP-gene pairs. 255 Given that *trans*-eQTL analyses are more prone to be affected by systematic errors between 256 genomic regions than cis-eQTLs [27], we only considered cis-eGenes. Several of the associated 257 *cis-eGenes* play a functional role in PD and are found to be significant in GTEx v8 analyses, 258 expressed in brain tissues [28]. The *cis-eGenes* include known PD-associated genes such as the 259 ubiquitin ligase NEDD4 which is protective against α -synuclein accumulation and toxicity 260 in animal models of PD [29], AGO2 which co-participates with PD gene LRRK2 [30], KIF1A 261 which is a key regulator of neural circuit deterioration in aging leading to intellectual disability, 262 muscle weakness, etc. [31], and LRTM1 whose cells survive and differentiate into midbrain 263 dopaminergic neurons in vivo resulting in significant improvement in motor behavior [32]. 264 In addition, several of the genes are known to be expressed in the brain but not previously 265 implicated in PD. Details about the protein-coding *cis-eGenes* and their expression in brain 266 and other tissues can be found in Supplementary Table A. 267

We evaluated the performance of the $24 \ cis$ -eGenes in disease classification with machine 268 learning methods on the blood-based gene expression data. The best performing method 269 on the 75% training set was SVM with RBF kernel (Supplementary Figure 4). SVM (RBF 270 kernel) resulted in an F_1 score of 0.61 with precision and recall of 0.62 and 0.65, respectively 271 on the 25% test set. This result was statistically significant (permutation test *p*-value 0.009). 272 When we applied the SVM classification using all the genes in the RNA-seq data, we observed 273 a similar F_1 score of 0.62 as well as similar precision (0.63) and recall (0.66) on the test set 274 (Table 1). Hence, the 24 cis-eGenes preserve the performance of the entire set of 34,386 genes 275 when classifying PD cases vs. healthy subjects. 276

Status	Precision	Recall	F_1 score
cis-eGenes HC	0.53	0.24	0.33
cis-eGenes PD	0.67	0.88	0.76
cis-eGenes Total	0.62	0.65	0.61
All genes Total	0.63	0.66	0.62

Table 1: Classification performance of the 24 *cis-eGenes*, compared to using all genes.

277

KEGG pathway enrichment analysis of the 24 cis-eGenes revealed one statistically signifi-

cant pathway, inositol phophate metabolism (Supplementary Figure 6). Phosphatidylinositol 4,5 biphosphate enhances the presence of α -synuclein's membrane association [33]. Inositolphosphate signaling pathway may act to reduce autophagy and in turn play a vital role in neurodegeneratie diseases [34] such as PD (due to a decline in autophagy).

3.3 CuNA reveals genotype-phenotype relationships

We combined for CuNA the gene expression data on the *cis-eGenes* and the motor and nonmotor phenotypes obtained from the PPMI study which included the MDS-UPDRS features, HY scale, age, sex, etc. We computed the cumulants to find higher-order interactions between all the features (including *cis-eGenes*). The cumulants' ability to separate higher-order moment contributions from possibly strong lower-order terms is highly desirable, and shows separability when applied to PPMI data contrasted with binomial tests of pattern significance.

Starting from 15,275 sets of features with similar patterns we filtered for significance by applying a threshold for p < 1e - 6 and FDR< 0.05 and obtained 761 significant sets of features. We constructed the network of dense interactions among all the associated features from these sets. The gene SAMD1 and the MDS-UPDRS variable *NP2SWAL* (chewing and swallowing issues) play central roles in the network with the top 20% of the edges (Supplementary Figure 3). Allowing more edges make the network denser and does not add new nodes (features). Hence, for visualization purposes we use the top 20% of the edges.

To disentangle the interactions between genes and PD phenotypes we performed community detection on the network (Supplementary Figure 3) and obtained the following community clusters:

299

– A cluster with variables Dx (diagnosis) and NHY (Hoehn-Yahr scale).

- A second cluster with the variable NP2SWAL playing a central role with other non-motor
 symptoms such as NP2SALV (saliva and drooling) and NP2SPCH (speech). Other fea tures such as NP1FATG (fatigue), NP1LTHD (light headedness) and NP1SLPD (day time sleepiness) also interact in this cluster.
- A third cluster with the gene SAMD1 interacting with MDS-UPDRS variables such as
 NP1PAIN (pain), NP1WALK (walking and balance), NP1CNST (constipation) and
 NP1URIN (urinary problems). Genes such as INPP5J and OR4K13 along with the
 phenotype Olfact are also present.
- For visualizing the communities in detail, we computed the Maximum Spanning Tree (MST) (Figure 3) of the entire network (Supplementary Figure 3).



Figure 3: Maximum Spanning Tree (MST) of the network generated by embedding higher-order cumulants. Nodes representing phenotypes and genes have black and blue labels, respectively. Edge widths are directly proportional to their weights. Color of nodes relate to their degree, red being the highest and green being lowest.

The first community with the variables Dx and NHY are straightforward to interpret as 310 PD diagnosis and HY scale are instrumental tools to understand the disease progression. The 311 second community contains MDS-UPDRS variables which are all related to the movement 312 of mouth muscles with saliva, drooling, speech and swallowing. Also present are variables 313 related to dizziness and fatigue such as light-headedness, daytime sleepiness, etc. which are 314 all early symptoms of PD. Lastly, and most importantly, we observe the gene SAMD1 plays 315 a very crucial and central role in the network. SAMD1 is expressed in blood and immune 316 system including T lymphocytes as well as in brain tissues. T lymphocytes have been shown 317 to recognize α -synuclein peptides in PD patient [35] and thus we present evidence for a 318 previously unreported association of the gene SAMD1 in PD diagnosis and early symptoms. 319 The gene INPP5J is also present in the cluster and is known to be associated in Lowe syndrome 320 which causes renal failure and affects the brain. Here, likewise, it interacts with MDS-UPDRS 321 variables related to constipation and urinary problems in early onset PD. Also present in the 322 cluster is the gene OR4K13 (Olfactory receptor gene) which interacts with the phenotype 323 Olfact capturing olfactory problems in early onset PD patients. Thus, CuNA reveals the 324 relationships with genes and clinical features of PD as represented by MDS-UPDRS variables, 325 HY scale, etc. decoding the heterogeneity of the clinical features of PD. 326

327

4 Discussion

The cumulant-based network analysis, CuNA, introduced here, can be used to detect genes 328 associated with clinical features in higher-dimensional space, adding granular view in contrast 329 to traditional case-control studies. There is a dearth of methods addressing the genetic associ-330 ations and underlying biological pathways of the symptoms and clinical features of idiopathic 331 PD or other complex diseases. This approach provides a framework integrating genotype, 332 gene expression and endophenotypes as input and finds relationships between them. eQTLs 333 and genotype-phenotype interactions are often plagued by false positives due to uncorrected 334 confounding effects such as population structure, environmental factors, etc. Hence, it is im-335 portant to test the robustness of CuNA to find whether it captures true biomarkers associated 336 with phenotypes of interest. We designed CuNAsim, a fast and efficient multi-omics simulator 337 which supports an array of phenotypes or clinical features to be tested alongside genotypes and 338 gene expression data. The "piped" algorithm structure of CuNA takes in input the simulated 339 data from CuNAsim and accurately captures the correlated features in forms of communities 340 in the network. Thus, CuNA is robust under different simulation scenarios and accurately 341

342 finds true associations.

CuNA computes cumulants in the form of redescription groups. Cumulants are higher-343 order moments and thus expensive to compute. Higher-order cumulants play an important 344 role in the analysis of non-normally distributed multivariate data and the computational com-345 plexity increases with the order by a factor of n^d , where d is the order of the cumulant and n is 346 the number of marginal variables. In genomics parlance, this creates a computational bottle-347 neck as the number of variables are in the order of hundreds of thousands with the decreasing 348 cost of sequencing. Thus CuNA undergoes a computational bottleneck in the cumulant com-349 putation with increasing number of variables. Advances in randomized algorithms and tensor 350 decomposition allows for faster computation of cumulants. A possible future direction is to 351 make CuNA faster by leveraging super-symmetric tensors in block structures and efficient 352 cumulant computation. 353

Applying CuNA to a Parkinson's disease data set of genotype and RNA-seq expression 354 data from blood samples with associated multitude of phenotypic measurements, we found 355 several novel candidate genes associated with PD phenotypes. We run CuNA on the candidate 356 significant *cis-eGenes* obtained by computing eQTLs. These *cis-eGenes* captured similar case-357 control classification performance as the whole data set. They were also enriched in the inositol 358 phosphate metabolism pathway which is linked with neurodegenerative diseases such as PD. 359 Thus, the *cis-eGenes* have both biological and statistical significance in the context of PD. 360 As latent population stratification can lead to spurious eQTLs and confound the study, we 361 included the top twenty PCs as covariates in the analysis. CuNA reveals cliques associated 362 with related biological functions such as constipation, urination and renal failure and the 363 gene INPP5J which is implicated in Lowe Syndrome and is found to be significant in both 364 brain and kidney cortex tissues in GTEx analysis (Supplementary Table A). MDS-UPDRS 365 measures were found to be associated with genes such as SAMD1 which is expressed in blood 366 and immune system as well as brain tissues. Blood-based gene expression such as analyzed 367 here has shown similarity with brain-based expression and is an intriguing noninvasive option 368 for capturing neurodegenerative disease progression [36]. 369

CuNA can disentangle the complex higher-order genotype-phenotype interactions, embed them in a network and analyze it. Network analysis and community detection approaches provide a deeper understanding of association studies involving eQTLs and phenotypes of interest with a visualization tool. The hyper-parameters and user-defined parameter thresholds can be varied to observe robustness and sensitivity of the method in handling false positives.

375 5 Conclusion

Associations between genotype, gene expression and phenotype data can be complex and often confounded by various environmental factors. We propose a novel framework CuNA to identify associations with more granularity than a standard case-control association study. We demonstrate that CuNA captures true associations by applying it on simulated data as obtained from our novel multi-omics simulator CuNAsim. When applied to PD diagnostic data encompassing clinical features along with motor and non-motor symptoms, CuNA identifies novel gene-phenotype relationships while replicating already known associations with PD.

GWAS has the potential to find loci with common genetic variants contributing to disease 383 risk. It has been extensively used in PD finding genes associated with disease risk. However, in 384 progressive diseases such as PD, Alzheimer's, cancer, cardiovascular diseases, etc. with a rich 385 repository of phenotypes or clinical features, it is of significance to study the genes associated 386 with an ensemble of the features sharing similar biological pathway. CuNA provides an exciting 387 opportunity to decode phenotypic and genotypic diversity and discover genes associated with 388 various manifestations of complex diseases, paving the way for future biomarker discovery and 389 personalized therapeutics. 390

391

6 Acknowledgements

Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org.

395 **References**

- [1] Billingsley, K., Bandres-Ciga, S., Saez-Atienzar, S., and Singleton, A. (2018). Genetic
 risk factors in Parkinson's disease. *Cell and tissue research* 373(1), 9–20.
- [2] Nica, A. C. and Dermitzakis, E. T. (2013). Expression quantitative trait loci: present and
 future. *Philosophical Transactions of the Royal Society B: Biological Sciences* 368(1620),
 20120362.
- [3] Gilad, Y., Rifkin, S. A., and Pritchard, J. K. (2008). Revealing the architecture of gene regulation: the promise of eQTL studies. *Trends in genetics* 24(8), 408–415.
- [4] Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T.,
 Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009). Genome-wide association study
 identifies common variants at four loci as genetic risk factors for Parkinson's disease. *Nature genetics* 41(12), 1303–1307.
- [5] Nalls, M., Plagnol, V., Hernandez, D., Sharma, M., Sheerin, U., Saad, M., SimónSánchez, J., Schulte, C., Lesage, S., Sveinbjörnsdóttir, S., et al. (2011). International
 Parkinson Disease Genomics Consortium Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association
 studies. Lancet 377(9766), 641–649.
- [6] Latourelle, J. C., Dumitriu, A., Hadzi, T. C., Beach, T. G., and Myers, R. H. (2012).
 Evaluation of Parkinson disease risk variants as expression-QTLs. *PloS one* 7(10), e46199.
- ⁴¹⁴ [7] Corti, O., Lesage, S., and Brice, A. (2011). What genetics tells us about the causes and ⁴¹⁵ mechanisms of Parkinson's disease. *Physiological reviews* **91**(4), 1161–1218.
- [8] Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson's disease. *The Lancet* 373(9680),
 2055 2066.
- [9] DeMaagd, G. and Philip, A. (2015). Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. *Pharmacy and therapeutics* 40(8), 504.
- [10] Mm, H. (1967). Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* **17**(5), 427–442.
- [11] Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin,
 P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSUPDRS): scale presentation and clinimetric testing results. *Movement disorders: official journal of the Movement Disorder Society* 23(15), 2129–2170.

- [12] Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., Van Der Brug, M., Cai,
 F., Kerchner, G. A., Ayalon, G., Bingol, B., Sheng, M., et al. (2017). A meta-analysis
 of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nature genetics* 49(10), 1511.
- [13] Tolosa, E., Gaig, C., Santamaría, J., and Compta, Y. (2009). Diagnosis and the premotor
 phase of Parkinson disease. *Neurology* 72(7 Supplement 2), S12–S20.
- [14] Greenland, J. C., Williams-Gray, C. H., and Barker, R. A. (2019). The clinical het erogeneity of Parkinson's disease and its therapeutic implications. *European Journal of Neuroscience* 49(3), 328–338.
- [15] Horsager, J., Andersen, K. B., Knudsen, K., Skjærbæk, C., Fedorova, T. D., Okkels, N.,
 Schaeffer, E., Bonkat, S. K., Geday, J., Otto, M., et al. 08 (2020). Brain-first versus
 body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* 143(10),
 3077–3088.
- [16] Chung, R.-H. and Kang, C.-Y. (2019). A multi-omics data simulator for complex disease
 studies and its application to evaluate multi-omics data analysis methods for disease
 classification. *GigaScience* 8(5), giz045.
- [17] Mandal, S., Guzmán-Sáenz, A., Haiminen, N., Basu, S., and Parida, L. (2020). A
 Topological Data Analysis Approach on Predicting Phenotypes from Gene Expression
 Data. In Algorithms for Computational Biology, Martín-Vide, C., Vega-Rodríguez, M. A.,
 and Wheeler, T., editors, 178–187 (Springer International Publishing, Cham, 2020).
- [18] Girvan, M. and Newman, M. E. (2002). Community structure in social and biological
 networks. *Proceedings of the national academy of sciences* 99(12), 7821–7826.
- [19] Shabalin, A. A. (2012). Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* 28(10), 1353–1358.
- [20] Bose, A., Kalantzis, V., Kontopoulou, E.-M., Elkady, M., Paschou, P., and Drineas, P.
 (2019). TeraPCA: a fast and scalable software package to study genetic variation in tera-scale genotypes. *Bioinformatics* 35(19), 3679–3683.
- [21] Chawla, N. V., Bowyer, K. W., Hall, L. O., and Kegelmeyer, W. P. (2002). SMOTE:
 synthetic minority over-sampling technique. *Journal of artificial intelligence research* 16, 321–357.
- [22] Huang, K. April (2010). Quantum Field Theory: From Operators to Path Integrals.
 Wiley-VCH, Weinheim, 2nd edition edition.

- [23] Rassoul-agha, F. and Seppalainen, T. March (2015). A Course on Large Deviations With
 an Introduction to Gibbs Measures. American Mathematical Society, Providence, Rhode
 Island.
- [24] McCullagh, P. July (2018). Tensor Methods in Statistics: Second Edition. Dover Publi cations, Mineola, New York, revised, updated edition edition.
- [25] Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R package for
 comparing biological themes among gene clusters. *Omics: a journal of integrative biology* **16**(5), 284–287.
- [26] Kanehisa, M. and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes.
 Nucleic acids research 28(1), 27–30.
- 470 [27] Saha, A. and Battle, A. (2018). False positives in trans-eQTL and co-expression analyses
 471 arising from RNA-sequencing alignment errors. *F1000Research* 7.
- [28] Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters,
 G., Garcia, F., Young, N., et al. (2013). The genotype-tissue expression (GTEx) project. *Nature genetics* 45(6), 580–585.
- [29] Davies, S. E., Hallett, P. J., Moens, T., Smith, G., Mangano, E., Kim, H. T., Goldberg,
 A. L., Liu, J.-L., Isacson, O., and Tofaris, G. K. (2014). Enhanced ubiquitin-dependent
 degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal
 models of Parkinson's disease. Neurobiology of disease 64, 79–87.
- [30] Gonzalez-Cano, L., Menzl, I., Tisserand, J., Nicklas, S., and Schwamborn, J. C. (2018).
 Parkinson's disease-associated mutant LRRK2-mediated inhibition of miRNA activity is
 antagonized by TRIM32. *Molecular neurobiology* 55(4), 3490–3498.
- [31] Rivière, J.-B., Ramalingam, S., Lavastre, V., Shekarabi, M., Holbert, S., Lafontaine, J.,
 Srour, M., Merner, N., Rochefort, D., Hince, P., et al. (2011). KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy
 type 2. The American Journal of Human Genetics 89(2), 219–230.
- [32] Samata, B., Doi, D., Nishimura, K., Kikuchi, T., Watanabe, A., Sakamoto, Y., Kakuta,
 J., Ono, Y., and Takahashi, J. (2016). Purification of functional human ES and iPSCderived midbrain dopaminergic progenitors using LRTM1. Nature communications 7(1),
 1–11.
- ⁴⁹⁰ [33] Narayanan, V., Guo, Y., and Scarlata, S. (2005). Fluorescence studies suggest a role ⁴⁹¹ for α -synuclein in the phosphatidylinositol lipid signaling pathway. *Biochemistry* **44**(2), ⁴⁹² 462–470.

- [34] Berridge, M. J. (2016). The inositol trisphosphate/calcium signaling pathway in health
 and disease. *Physiological reviews* 96(4), 1261–1296.
- [35] Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C.,
 McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017). T cells from patients with
 Parkinson's disease recognize α-synuclein peptides. Nature 546(7660), 656–661.
- [36] Iturria-Medina, Y., Khan, A. F., Adewale, Q., Shirazi, A. H., and the Alzheimer's Disease
 Neuroimaging Initiative. 01 (2020). Blood and brain gene expression trajectories mirror
 neuropathology and clinical deterioration in neurodegeneration. *Brain* 143(2), 661–673.
- [37] Servin, B. and Stephens, M. (2007). Imputation-based analysis of association studies:
 candidate regions and quantitative traits. *PLoS genetics* 3(7).
- ⁵⁰³ [38] Abecasis, G. R., Cherny, S. S., Cookson, W. O., and Cardon, L. R. (2002). Merlin—rapid ⁵⁰⁴ analysis of dense genetic maps using sparse gene flow trees. *Nature genetics* **30**(1), 97–101.
- [39] Hoggart, C. J., Whittaker, J. C., De Iorio, M., and Balding, D. J. (2008). Simultaneous
 analysis of all SNPs in genome-wide and re-sequencing association studies. *PLoS genetics* 4(7).
- [40] Marazziti, D., Di Pietro, C., Golini, E., Mandillo, S., Matteoni, R., and Tocchini Valentini, G. P. (2009). Macroautophagy of the GPR37 orphan receptor and Parkinson
 disease-associated neurodegeneration. Autophagy 5(5), 741–742.
- [41] Jayapalan, S., Subramanian, D., and Natarajan, J. (2016). Computational identification
 and analysis of neurodegenerative disease associated protein kinases in hominid genomes.
 Genes & diseases 3(3), 228–237.
- [42] Berger, B. S., Acebron, S. P., Herbst, J., Koch, S., and Niehrs, C. (2017). Parkinson's disease-associated receptor GPR 37 is an ER chaperone for LRP 6. *EMBO reports* 18(5), 712–725.

⁵¹⁷ Supplementary Materials



Figure 4: QQ plot showing statistical significance of *cis* (Local p-values, red) and *trans* (Distant p-values, blue) eQTLs.

518 eQTL analysis

The goal of eQTL analysis is to identify SNPs which are significantly associated with expression 519 of known genes. They reveal complex biological processes underlying diseased systems and 520 help discover latent genetic factors causing certain diseases. Most eQTL studies perform 521 separate association tests for each transcript-SNP pair. Association testing can be done in 522 a straightforward manner by linear regression ar ANOVA models and if required, non-linear 523 techniques such as generalized linear and mixed models, Bayesian regression [37], accounting 524 for pedigree [38], etc. Many methods have been developed to find groups of SNPs associated 525 with expression of a single gene [8, 39]. With the advancement of sequencing techniques and 526 decreasing cost there has been an unprecedented growth in genotype and expression level data. 527 As eQTL studies identify SNPs which are significantly associated with expression of known 528 genes, they can be computationally intensive resulting in billions of associations for large scale 529 data. The simple linear regression is one of the most commonly used methods for eQTLs. 530

$$y = \alpha + \beta s + \epsilon \tag{4}$$

where $\epsilon \sim i.i.d \ N(0, \sigma^2)$. The number of such tests can easily result in billions. Instead, if we let **G** is the gene expression matrix, with each row containing measurements for a single gene across individuals and **S** be the genotype matrix, with each row containing measurements for a single SNP across individuals. Then the matrix of all gene-SNP correlations can be calculated

in one large matrix multiplication. Thus we have,

$$\mathbf{Y} = \mathbf{G}\mathbf{S}^T \tag{5}$$

The correlations are thus computed in Equation 5 and we report the corresponding test statistic, p-value, FDR, etc.

538 Redescriptions

535

Subjects $s \in S$ are described by a list of features $f_i(s)$ indexed by feature labels $i \in \mathcal{F}$. Each feature has an alphabet \mathcal{A}_i so that $f_i(s) \in \mathcal{A}_i$. That alphabet is often binary, but could be defined on the reals. Examples of binary features in \mathcal{F} are diagnoses (Dx) such as hypertension (HT) or type-II diabetes (T2D), or body mass index (bmi) which would have a continuum alphabet ($\mathcal{A}_{bmi} = \mathbb{R}$).

For a given $a_i \in \mathcal{A}_i$, the set of subjects that have that value is $f_i^{-1}(a_i) \subseteq \mathcal{S}$. So the list of subjects with hypertension can be written $f_{HT}^{-1}(1)$. In the case of continuous variables, the selection of sets is according to a threshold, such as the mean $m(f_i(S))$, mapped to 1 if $f_i(s) \ge m(f_i(S))$.

Patterns may be described in terms of conjunctions $i \wedge j$ for $i, j \in \mathcal{F}$ such that $f_{i \wedge j}^{-1}(a_i, a_j) =$ $f_i^{-1}(a_i) \cap f_j^{-1}(a_j)$ for binary a_i, a_j . This definition is extended to include either atomic i, j, such as HT or T2D, or coronary artery disease (CAD), or to any combinations of conjunctions subject to the logical algebra of \wedge (e.g. $(i \wedge j) \wedge (i \wedge k) = i \wedge j \wedge k$ for $i, j, k \in \mathcal{F}$ subject to values a_i, a_j, a_k . So we can specify the diabetic hypertensive subjects as $f_{T2D \wedge HT}^{-1}(T2D =$ 1, HT = 1). Such combinations of conjunctions i that have more or less members $f_i^{-1}(a)$ than expected by chance are called patterns.

555 556 Binomial and other tests of the significance of patterns can be dominated by lower-order correlations among the variables in a pattern.

Two distinct patterns that yield the same subsets of subjects, e.g. $f_i^{-1}(a) = f_j^{-1}(a)$, are called "redescriptions." If conjunctions yield a form such as $A \cap B = B$, then it may be deduced that $B \subset A$, and the conditions yielding A and B satisfy $b \Rightarrow a$. In other words, redescriptions can reveal logical relationships among features. Such relationships may reflect underlying biological pathways reflected in these connected phenotype patterns. Therefore, each of these patterns *i* specify a phenotype, which may be associated with genotypes or other -omic data using standard methods.

564

Given the presence of misclassifications, differential evolution of disease stages, simple

transcription mistakes, etc, result in errors in estimates of $f_i^{-1}(a)$ must be accounted for in estimating equivalence. We can use Jaccard distances $d = 1 - \frac{|A \cap B|}{|A \cup B|}$ measures deviations. So $d(A \cup B, B) = 1 - \frac{|A \cup |}{|B|}$ is 0 if $B \subseteq A$, some non-zero value with any $B \nsubseteq A$. This distance measures the probability that samples drawn from A and B are not shared, which gives an index for the possible to distinguish disruption due to errors, or whether it would be possible to distinguish non biological pathways vs. biological pathways with error.

⁵⁷¹ Population Structure

The PPMI data set has population structure which may confound the eQTL computation and therefore result in spurious associations in downstream CuNA computations. We observe a main cluster of "RAWHITE" which relates to the Europeans and Caucasian ethnicities present in the data set. Another cluster appears in the scatterplot of the top two PCs (Figure 5) related to the "RABLACK" or the African ethnicities in the data. These legends are defined by the PPMI study.



Figure 5: Scatterplot of the top two PCs computed on the genotype data reveals the population structure in PPMI data set (456 individuals).

577



Figure 6: Interaction networks between genes and PD phenotypes with only top 20% of the edges present. Genes are highlighted in blue and phenotypes in black. The color of the nodes relate to their degrees, red being the highest and green being the lowest degree.



Figure 7: Classification performance comparison on training set with 24 eGenes and 75% of the 456 individuals (293 PD, 163 HC). We compare the Recall as we are more interested in the true positive classification and selected SVM with RBF kernel as it performed best.

Genetic variant	GTEx expression tissue	Brain Regions	Reported
rs60444836	Brain	AM	-
NEDD4	Brain	ALL	[29]
RNASE4	Brain	ALL	-
SLC25A51	Brain	ALL	-
LRTM1	Brain	AM, Anterior cingulate cortex, BG, CO, Frontal cortex, HI	[32]
CEACAM8	Brain	CH, CE, CO, SN	-
KIF18B	Brain	ALL	-
GPRC5B	Brain	ALL	[40]
AGO2	Brain, Pancreas, Liver, Whole blood, Lung, Stomach, Kidney cortex, etc.	ALL	[30]
ROS1	Brain	ALL	[41]
AC097721	Brain	BG, HI, HY, SCC, SN	-
CTB-5506.12	Brain	ALL	-
KIF1A	Brain	ALL	[31]
FAM225B	Brain, Prostate, Uterus, Ovary, Thyroid, etc.	ALL	-
SAMD1	Brain, Whole blood, Liver, Kidney Cortex, Stomach, etc.	ALL	-
INPP5J	Brain, Adipose, Uterus, Whole blood, Ovary, Lung, Liver, Kidney cortex, Stomach, etc.	ALL	-
LRP6	Brain, Whole blood, Skin, Ovary, Kidney cortex, etc.	ALL	[42]
ENY2	Brain, Whole blood, Stomach, Liver, Lung, Kidney cortex, etc.	ALL	-
DPMI1	Brain, Whole blood, Skin, Pan- creas, Stomach, Thyroid, Liver, etc.	ALL	_

Table 2: One *cis*-eSNP (other *cis*-eSNPs are not associated with expression in brain) and 18 protein-coding *cis*-eGenes highlighted by eQTL analysis (remaining 6 out of 24 *cis*-eGenes are pseudogenes). The tissues they are expressed in (GTEx v8), along with the reported regions in the brain are shown. Previously reported implications in PD are cited when available. ALL brain regions include: Amygdala (AM), Basal ganglia (BG), Cerebellum (CE), Cortex (CO), Cerebellar hemisphere (CH), Hippocampus (HI), Hypothalamus (HY), Spinal cord cervical (SCC), Substantia nigra (SN).



Figure 8: Network of the simulated variables colored by degrees of each node (darker colors have more degree). The correlation matrix of the variables is shown in the inset with the color gradient.

Table 3: μ for multivariate Gaussian distribution and standard variation σ for each parameter in the first simulation scenario.

Features	μ	σ
Standard variation	0.5	1.34
Pheno1	0.5	1.16
Pheno2	-0.1	2
SNP0	0.3	1.81
SNP0	0.1	1.81
SNP1	0.3	1.72
SNP1	0.5	1.72
SNP2_0	0.5	1
SNP2_1	0.5	1
Gene0	1	5.16
Gene1	1	5.16
Gene2	3	5.16
Gene3	3	5.16
Gene4	3	3

Table 4: Baseline proportions for binary variates computed from multivariate distributions corresponding to case-control proportions and MAFs in the first simulation scenario.

P_L
0.667
0.679
0.48
0.588
0.53
0.59
0.648
0.691
0.691

$ $ L_1	L_2	OR	$ P_{L_1 L_2} $	$ P_{L_1 \bar{L}_2}$	$ P_{L_2 L_1} $	$ P_{L_2 \bar{L}_1} $
Pheno0	Pheno1	7.093	0.807	0.371	0.821	0.393
Pheno0	Pheno2	1	0.667	0.667	0.48	0.48
Pheno0	SNP0_0	2.87	0.764	0.529	0.673	0.418
Pheno0	SNP0_1	2.875	0.775	0.545	0.615	0.358
Pheno0	SNP1_0	1	0.667	0.667	0.59	0.59
Pheno0	SNP1_1	1	0.667	0.667	0.648	0.648
Pheno0	SNP2_0	1	0.667	0.667	0.691	0.691
Pheno0	SNP2_1	1	0.667	0.667	0.691	0.691
Pheno1	Pheno2	1	0.679	0.679	0.48	0.48
Pheno1	SNP0_0	1.244	0.698	0.651	0.605	0.552
Pheno1	SNP0_1	1.243	0.701	0.654	0.547	0.493
Pheno1	SNP1_0	1	0.679	0.679	0.59	0.59
Pheno1	SNP1_1	1	0.679	0.679	0.648	0.648
Pheno1	SNP2_0	1	0.679	0.679	0.691	0.691
Pheno1	SNP2_1	1	0.679	0.679	0.691	0.691
Pheno2	SNP0_0	1	0.48	0.48	0.588	0.588
Pheno2	SNP0_1	1	0.48	0.48	0.53	0.53
Pheno2	SNP1_0	1	0.48	0.48	0.59	0.59
Pheno2	SNP1_1	1	0.48	0.48	0.648	0.648
Pheno2	SNP2_0	1	0.48	0.48	0.691	0.691
Pheno2	SNP2_1	1	0.48	0.48	0.691	0.691
SNP0_0	SNP0_1	3.407	0.724	0.435	0.652	0.355
SNP0_0	SNP1_0	1	0.588	0.588	0.59	0.59
SNP0_0	SNP1_1	1	0.588	0.588	0.648	0.648
SNP0_0	SNP2_0	1	0.588	0.588	0.691	0.691
SNP0_0	SNP2_1	1	0.588	0.588	0.691	0.691
SNP0_1	SNP1_0	1	0.53	0.53	0.59	0.59
SNP0_1	SNP1_1	1	0.53	0.53	0.648	0.648
SNP0_1	SNP2_0	1	0.53	0.53	0.691	0.691
SNP0_1	SNP2_1	1	0.53	0.53	0.691	0.691
SNP0_1	SNP1_0	3.16	0.688	0.411	0.755	0.494
SNP0_1	SNP2_0	1	0.59	0.59	0.691	0.691
SNP0_1	SNP2_1	1	0.59	0.59	0.691	0.691
SNP1 0	SNP2 0	1	$29 \\ 0.648$	0.648	0.691	0.691

Table 5: Odds ratios and proportions of binary measures given either phenotype state or allele in the first simulation scenario.

Features	mu	sigma
Pheno0	0.5	2.28
Pheno1	0.5	2.45
Pheno2	-0.1	2
SNP0_0	0.3	1
SNP0_1	0.1	1.81
SNP1_0	0.3	1
SNP1_1	0.5	1
SNP2_0	0.5	1.64
SNP2_1	0.5	1
Gene0	1	5.43
Gene1	1	5.43
Gene2	3	3
Gene3	3	7.86
Gene4	3	3

Table 6: μ for multivariate Gaussian distribution and standard variation σ for each parameter in the second simulation scenario.

Table 7: Baseline proportions for binary variates computed from multivariate distributions corresponding to case-control proportions and MAFs in the second simulation scenario.

-

L	P_L
Pheno0	0.63
Pheno1	0.625
Pheno2	0.48
SNP0_0	0.618
$SNP0_1$	0.53
$SNP1_0$	0.618
$SNP1_1$	0.691
$SNP2_0$	0.652
$SNP2_1$	0.691

L_1	L_2	OR	$ P_{L_1 L_2} $	$ P_{L_1 \bar{L}_2} $	$P_{L_2 L_1}$	$P_{L_2 \bar{L}_1}$
Pheno0	Pheno1	8.055	0.804	0.338	0.799	0.33
Pheno0	Pheno2	1	0.63	0.63	0.48	0.48
Pheno0	SNP0_0	1	0.63	0.63	0.618	0.618
Pheno0	$SNP0_1$	1	0.63	0.63	0.53	0.53
Pheno0	SNP1_0	1	0.63	0.63	0.618	0.618
Pheno0	SNP1_1	1	0.63	0.63	0.691	0.691
Pheno0	SNP2_0	19.026	0.846	0.224	0.876	0.271
Pheno0	$SNP2_1$	1	0.63	0.63	0.691	0.691
Pheno1	Pheno2	1	0.625	0.625	0.48	0.48
Pheno1	SNP0_0	1	0.625	0.625	0.618	0.618
Pheno1	$SNP0_1$	1	0.625	0.625	0.53	0.53
Pheno1	SNP1_0	1	0.625	0.625	0.618	0.618
Pheno1	SNP1_1	1	0.625	0.625	0.691	0.691
Pheno1	SNP2_0	2.365	0.696	0.492	0.726	0.528
Pheno1	$SNP2_1$	1	0.625	0.625	0.691	0.691
Pheno2	SNP0	1	0.48	0.48	0.618	0.618
Pheno2	SNP1	1	0.48	0.48	0.53	0.53
Pheno2	SNP2	1	0.48	0.48	0.618	0.618
Pheno2	$SNP1_1$	1	0.48	0.48	0.691	0.691
Pheno2	$SNP2_0$	1	0.48	0.48	0.652	0.652
Pheno2	$SNP2_1$	1	0.48	0.48	0.691	0.691
SNP0_0	SNP1	1	0.618	0.618	0.53	0.53
$SNP0_0$	SNP2	1	0.618	0.618	0.618	0.618
$SNP0_0$	$SNP1_1$	1	0.618	0.618	0.691	0.691
$SNP0_0$	$SNP2_0$	1	0.618	0.618	0.652	0.652
$SNP0_0$	$SNP2_1$	1	0.618	0.618	0.691	0.691
$SNP0_1$	SNP2	1	0.53	0.53	0.618	0.618
$SNP0_1$	SNP1_1	1	0.53	0.53	0.691	0.691
$SNP0_1$	$SNP2_0$	1	0.53	0.53	0.652	0.652
$SNP0_1$	$SNP2_1$	1	0.53	0.53	0.691	0.691
$SNP1_0$	SNP1_1	1	0.618	0.618	0.691	0.691
$SNP1_0$	$SNP2_0$	1	0.618	0.618	0.652	0.652
$SNP1_0$	$SNP2_1$	1	0.618	0.618	0.691	0.691
SNP1_1	$SNP2_0$	1	0.691	0.691	0.652	0.652
$SNP1_1$	$SNP2_1$	1	0.691	0.691	0.691	0.691
SNP2_0	SNP2_1	1	0.652	0.652	0.691	0.691

Table 8: Odds ratios and proportions of binary measures given either phenotype state or allele in the second simulation scenario.